| Human KRAS WT (HLA-A*03:01) Protein (LTP10198) |
| LTP10198 |
| 100ug |
|
$406 In stock |
| Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. |
| Recombinant Human KRAS WT(HLA-A*03:01) Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide. |
| KRAS WT (HLA-A*03:01) |
| Human |
| NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVVGAGGVGK |
| Gly25-Thr305(HLA-A*03:01) & Ile21-Met119(B2M)and VVVGAGGVGK peptide |
| The protein has a predicted MW of 50.2 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on the Tris-Bis PAGE result. |
| 0 |
| C-His-Avi |
| Expi293 |
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Less than 1EU per ug by the LAL method. |
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipped at ambient temperature. |
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| ![Human KRAS WT (HLA-A*03:01) Protein (LTP10198)](/peptide-product/images/protein-products/LTP10198/20211214193739.png) |